

## CORPORATE PROFILE

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies and the company generates more than \$5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit [www.biogenidec.com](http://www.biogenidec.com).

## STOCK PERFORMANCE

### BIIB (COMMON STOCK)

Exchange NASDAQ (US Dollar)  
 Price **\$347.64**  
 Change (%) **▲ 5.23 (1.53%)**  
 Volume 1,190,927  
 52 Week Low \$244.28  
 Market Cap \$73,517,842,031  
 Rolling EPS 16.31  
 PE Ratio 21.3145  
 Shares Outstanding 211,476,936  
 Data as of 01/22/18 4:00 p.m. ET



## RECENT PRESS RELEASES

- 01/04/18  
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing
- 12/19/17  
Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
- 12/04/17  
Biogen Appoints Mark Hernon as SVP, Chief Information Officer
- 11/27/17  
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
- 11/21/17  
Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer

## UPCOMING EVENTS

There are currently no events scheduled.

## RECENT SEC FILINGS

FILING DATE	FORM
01/10/18	4
01/08/18	4/A
01/04/18	4
01/02/18	4
12/18/17	3

## ANALYST ESTIMATES / RATINGS

Mean Recommendation: **2.1**



Sell

Strong Buy

Unable to fulfill request.

## OWNERSHIP SUMMARY

	Holders	Value (\$MM)	% O/S	Shares
Institution	1,481	60,743.91	91.9	194,279,578
Mutual Fund	2,650	36,129.27	54.5	115,179,575
Insider *	22	66.33	0.1	248,857

*\*Insider values reflect direct beneficial ownership.*

	Shares Held	% O/S	Share Change	Filing Date
PRIMECAP Management Company	15,212,914	7.2	-178,487	09/30/17
The Vanguard Group, Inc.	14,668,942	6.9	134,115	09/30/17
BlackRock Institutional Trust Company, N.A.	11,866,817	5.6	-320,324	09/30/17
T. Rowe Price Associates, Inc.	10,681,378	5.1	1,732,596	09/30/17
State Street Global Advisors (US)	9,669,416	4.6	-51,896	09/30/17
ClearBridge Investments, LLC	9,250,827	4.4	-43,073	09/30/17
Fidelity Management & Research Company	7,008,889	3.3	1,029,679	09/30/17
Wellington Management Company, LLP	5,167,662	2.4	-60,818	09/30/17
AllianceBernstein L.P.	2,687,665	1.3	283,918	09/30/17
Nuveen LLC	2,456,104	1.2	207,109	09/30/17

Powered By **EDGAR**Online

*Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.*

*Minimum 20 minutes delayed*